In the present study, we found that the expression levels of the MYL9 gene were also downregulated in COAD compared with the corresponding normal tissues, the OS (p = .0061) and DFS (p = .019) of the low MYL9 expression group were longer than the high MYL9 expression group, which were in accordance the result about the DFS of colon cancer patients in PrognoScan database and suggested that MYL9 could be used as a biomarker for COAD diagnosis and therapy. Here, MYL9 is linked to malignant colon neoplasm.